Abu Rous F,Singhi EK,Sridhar A,Faisal MS,Desai A .2023 .Lung cancer treatment advances in 2022. , 41(1) : 12-24.
Leung Bacchetti P,JM Bacchetti P .2022 .Sample size calculations in clinical research. , 97(4) : 1028-9.
Bum Lee J,Huang Y,Oya Y,Nutzinger J,LE Ang Y,Sooi K,Chul Cho B,Soo RA B .2024 .Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities. Lung Cancer, 194 : 107862.
Chen P,Liu Y,Wen Y,Zhou C Y .2022 .Non-small cell lung cancer in China. Cancer Commun (Lond), 42(10) : 937-970.
Chen X,Mo S,Yi B .2022 .The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories. BMC Public Health, 22(1) : 987.
Conroy MR,Dennehy C,Forde PM C .2023 .Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer. Lung Cancer, 183 : 107314.
Diez P,Hanna GG,Aitken KL,van As N,Carver A,Colaco RJ,Conibear J,Dunne EM,Eaton DJ,Franks KN,Good JS,Harrow S,Hatfield P,Hawkins MA,Jain S,McDonald F,Patel R,Rackley T,Sanghera P,Tree A,Murray L A .2022 .UK 2022 Consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin. Oncol. (R Coll. Radiol), 34(5) : 288-300.
Dong Q,Chen ES,Zhao C,Jin C C .2021 .Hostmicrobiome interaction in lung cancer. Front. Immunol., 12 : 679829.
Duttagupta S,Hakozaki T,Routy B,Messaoudene M .2023 .The gut microbiome from a biomarker to a novel therapeutic strategy for immunotherapy response in patients with lung cancer. Curr. Oncol., 30(11) : 9406-9427.
El Tekle G,Garrett WS G .2023 .Bacteria in cancer initiation, promotion and progression. Nat. Rev. Cancer, 23(9) : 600-618.
Farrington CP,Manning G .1990 .Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or nonunity relative risk. Stat. Med, 9(12) : 1447-54.
Freites-Martinez A,Santana N,Arias-Santiago S,Viera A .2021 .Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr. (Engl Ed), 112(1) : 90-92.
Guo H,Zhang J,Qin C,Yan H,Liu T,Hu H,Tang S,Tang S,Zhou H S .2022 .Biomarker-targeted therapies in non-small cell lung cancer: Current status and perspectives. , 11(20) : 3200.
Han Y,Liu D,Li L D .2020 .PD-1/PD-L1 pathway: Current researches in cancer. Am. J. Cancer Res., 10(3) : 727-742.
Jin Y,Dong H,Xia L,Yang Y,Zhu Y,Shen Y,Zheng H,Yao C,Wang Y,Lu S Y .2019 .The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol., 14(8) : 1378-1389.
Karlsen EA,Kahler S,Tefay J,Joseph SR,Simpson F SR .2021 .Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: A review. Cells, 10(5) : 1206.
Kelly K,Crowley J,Bunn PA,Presant CA,Grevstad PK,Moinpour CM,Ramsey SD,Wozniak AJ,Weiss GR,Moore DF,Israel VK,Livingston RB,Gandara DR .2001 .Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J. Clin. Oncol., 19(13) : 3210-3218.
Lee A,Keam SJ .2020 .Tislelizumab: First approval. Drugs, 80(6) : 617-624.
Li Y,Wang K,Zhang Y,Yang J,Wu Y,Zhao M .2023 .Revealing a causal relationship between gut micro biota and lung cancer: A Mendelian randomization study. Front. Cell Infect, 13 : 1200299.
Lu S,Wang J,Yu Y,Yu X,Hu Y,Ai X,Ma Z,Li X,Zhuang W,Liu Y,Li W,Cui J,Wang D,Liao W,Zhou J,Wang Z,Sun Y,Qiu X,Gao J,Bao Y,Liang L,Wang M,Thorac M .2021 .Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial. , 16(9) : 1512-1522.
Luo Y,Zhang Z,Guo X,Tang X,Li S,Gong G,Gao S,Zhang Y,Lin S Y .2023 .Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated nonsmall cell lung cancer: Systematic review and network meta-analysis. Lung Cancer, 184 : 107319.
Ma PJ,Wang MM,Wang Y .2022 .Gut microbiota: A new insight into lung diseases. , 155 : 113810.
Meyer ML,Fitzgerald BG,Paz-Ares L,Cappuzzo F,Jänne PA,Peters S,Hirsch FR .2024 .New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet, 404(10454) : 803-822.
Qian X,Zhang HY,Li QL,Ma GJ,Chen Z,Ji XM,Li CY,Zhang AQ .2022 .Integrated microbiome, metabolome and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer. Clin. Transl. Med, 12(6) : e947.
Schiller JH,Harrington D,Belani CP,Langer C,Sandler A,Krook J,Zhu J,Johnson DH .2002 .Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med, 346(2) : 92-8.
Schwartz LH,Litière S,de Vries E,Ford R,Gwyther S,Mandrekar S,Shankar L,Bogaerts J,Chen A,Dancey J,Hayes W,Hodi FS,Hoekstra OS,Huang EP,Lin N,Liu Y,Therasse P,Wolchok JD,Seymour L JD .2016 .. RECIST 1.1-Update and clarification: From the RECIST Committee. Eur. J. Cancer, 62 : 132-7.
Shah H,Ng TL H .2023 .A narrative review from gut to lungs: Non-small cell lung cancer and the gastrointestinal microbiome. Transl. Lung Cancer Res., 12(4) : 909-926.
Tian Z and Yao W .2022 .Albumin-bound Paclitaxel: Worthy of further study in sarcomas. , 12 : 815900.
Tsuruoka K,Tamura Y,Shimazu Y,Arai M,Mitsuya S,Funamoto T,Tsuji H,Matsunaga N,Nakamura T,Ikeda S,Kawabata S,Imagawa A,Fujisaka Y .2024 .Association between PD-L1 expression and efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer. Anticancer Res., 44(12) : 5531-5539.
Tu Z,Liao S,Chen C,Li C,Hu Q,Cai C,Yu Y,Luo J,Huang M .2021 .The long-term spatiotemporal trends in lung cancer burden and its risk factors at global, regional. (Lond.), 44(12) : 1418-1421.
Vernocchi P,Gili T,Conte F,Del Chierico F,Conta G,Miccheli A,Botticelli A,Paci P,Caldarelli G,Nuti M,Marchetti P,Putignani L P .2020 .Network analysis of gut micro biome and metabolome to discover micro biota-linked biomarkers in patients affected by non-small cell lung cancer. Int. J. Mol. Sci, 21(22) : 8730.
Wang J,Suo X,Zhang H X .2023 .P-glycoprotein antibody-conjugated paclitaxel liposomes targeted for multidrug-resistant lung cancer. Nanomedicine (Lond.), 18(10) : 819-831.
Yadegar A,Bar-Yoseph H,Monaghan TM,Pakpour S,Severino A,Kuijper EJ,Smits WK,Terveer EM,Neupane S,Nabavi-Rad A,Sadeghi J,Cammarota G,Ianiro G,Nap-Hill E,Leung D,Wong K,Kao D K .2024 .Fecal microbiota transplantation: Current challenges and future landscapes. Clin. Microbiol, 37(2) : e0006022.
Yardley DA .2013 .nab-paclitaxel mechanisms of action and delivery. J. Control Release, 170(3) : 365-372.
Zhao Y,Liu Y,Li S,Peng Z,Liu X,Chen J,Zheng X .2021 .Role of lung and gut microbiota on lung cancer pathogenesis. J. Cancer Res. Clin. Oncol., 147(8) : 2177-2186.
Zheng Y,Fang Z,Xue Y,Zhang J,Zhu J,Gao R,Yao S,Ye Y,Wang S,Lin C,Chen S,Huang H,Hu L,Jiang GN,Qin H,Zhang P,Chen J,Ji H J .2020 .Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes, 11(4) : 1030-1042.
Zhu J,Yu Y,Mei J,Chen S,Li J,Jiang S J .2023 .Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer. Front. Immunol., 14 : 1278573.